Anaveon presents ANV600, a novel development compound, at the 2023 American Association for Cancer Research Annual Meeting.

ANAVEON Biotech Cancer IL-2 Cytokines Bispecific Phase Clinical

Basel, April 18, 2023 – Anaveon presents ANV600, a novel development compound, at the 2023 American Association for Cancer Research Annual Meeting (download poster here).

Latest News

01.04.2025

Immuno-Oncology Progress: PragmaTIL Trial Receives Approval, with Anaveon as a Key Partner

As a key partner, we are proud to announce that PragmaTIL has received regulatory approval to launch its clinical trial, bringing safer and more effective cell therapy one step closer to cancer patients. 🔬 The trial will start at VHIO (Spain) and Herlev Hospital (Denmark),…
Read more

18.12.2024

Anaveon appoints Dr. Richard Sachse as Chief Medical Officer

Basel, December 18, 2024 – Anaveon, a clinical stage, immuno-oncology company, today announced the appointment of Richard Sachse, M.D., Ph.D., as Chief Medical Officer effective February 1, 2025. Dr. Sachse brings more than 25 years of experience in the biopharma industry as a physician and…
Read more

07.11.2024

Anaveon presents new data on development compounds ANV700 and ANV600 at the Society for Immunotherapy of Cancer 2024 Annual Meeting

Basel, Novmeber 9, 2024 – Anaveon, a clinical stage, immuno-oncology company, presents posters on ANV700 and ANV600 at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting being held from Friday, November 8, 2024, to Sunday, November 10, 2024, in Houston, Texas. Abstracts will…
Read more

Corporate Positioning & Design, Concept, Webdesign & Code:
Schlatter corporate GmbH
Davidstrasse 45
CH-9000 St.Gallen
schlattercorporate.com